ARS Pharmaceuticals announced no new payer coverage for its epinephrine nasal spray, neffy, in the July 2026 cycle but continues discussions and notes growing demand. The company lowered its 2026 operating expenses to $248 million, emphasizing cost discipline and prioritized investments. ARS Pharma reaffirmed that its neffy base business supports a path to cash-flow breakeven in 2027. Additionally, interim data from its Phase 2b trial for chronic spontaneous urticaria (CSU) treatment is expected in Q4 2026, highlighting potential future growth opportunities.
Breckenridge Distillery, a subsidiary of Tilray Brands, won top awards at the San Francisco World Spirits Competition. Their Rum Cask Finish received the highest honor, Double Gold with 97 points, while their Honey Whiskey earned a Gold medal. These ...
The global laboratory equipment services market, valued at $28.94 billion in 2025, is projected to grow to $62.83 billion by 2035 at an 8% CAGR. Growth is fueled by increased R&D investments, stricter regulatory compliance, and expanding biopharma an...
Reklaim Credit Solutions, a credit rating agency for the state-regulated cannabis industry, announced that co-founders Sam Fensterstock and Bob McCarthy have taken on executive roles as Chief Revenue Officer and Chief Technology Officer, respectively...
SIM swapping scams involve criminals hijacking your phone number by transferring it to a SIM or eSIM they control, allowing access to your bank and credit accounts without physical access to your phone. Since 2022, over 5,000 cases have been reported...
TRADEMARK, a global experiential marketing agency, won the Bronze Eventex Award for its exceptional work on Adobe MAX 2025, a major creative industry conference. The award highlights TRADEMARK's skill in blending creative ambition with precise execut...
